好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Comparison of Outcomes Between Patients with Different PD Subtypes in the AAN Axon Registry
Movement Disorders
P8 - Poster Session 8 (5:30 PM-6:30 PM)
3-016
To compare outcomes between Parkinson’s Disease (PD) subtypes using measures extracted from clinical notes from the AAN Axon Registry, a neurology-specific patient registry of real-world electronic health record data.
Akinesia/bradykinesia and rigidity-dominant (AR) and tremor-dominant (TD) subtypes have been identified in PD, with the latter demonstrating a milder progression. Leveraging real-world data (RWD) to identify subtypes and distinctions in disease progression enables application of RWD to the study of pharmaceutical targets based on subtype.

15,000 PD patients were identified using structured ICD codes and PD related keywords in clinical notes from 2.6 million patients in the Axon Registry. All measures were curated from clinical notes with the exception of deep brain stimulation (DBS), which was curated from linked claims data.

PD subtype was determined by calculating the tremor to rigidity/bradykinesia severity ratio at the earliest encounter within one year of the patient’s first PD ICD code. Patients were classified as TD for ratios >=1 and AR for ratios <0.8 (Kang et al., 2005). 

Subtypes were compared by presence and time to first presence of postural instability, motor fluctuations, dyskinesia, and DBS using chi-square and Mann-Whitney U tests, respectively. 


1764 and 693 PD patients were identified as AR and TD, respectively. The AR subtype had a higher proportion of patients with postural instability (61% vs. 53%) and dyskinesia (11% vs. 7%), p-values < .01 and a shorter time to first encounter with dyskinesia (mean 17 vs. 24 months) and motor fluctuations (mean 10 vs. 13 months), p-values < .05. No differences in DBS were found between subtypes. 

Using RWD, we were able to identify AR and TD subtypes and differences in progression profiles consistent with the previous literature, demonstrating that RWD can be leveraged for subtype studies and outcome differences within PD. 

Authors/Disclosures
Iris Chin, PhD (Verana Health)
PRESENTER
Dr. Chin has received personal compensation for serving as an employee of Verana Health.
Sarah Kranick, MD (MultiCare Health System) Dr. Kranick has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Verana Health.
Heather Moss, MD, PhD, FAAN (Spencer Center for Vision Research at Stanford) Dr. Moss has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Verana Health. Dr. Moss has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Legal Firms. The institution of Dr. Moss has received research support from NIH. The institution of Dr. Moss has received research support from Research to Prevent Blindness. Dr. Moss has received intellectual property interests from a discovery or technology relating to health care. Dr. Moss has received personal compensation in the range of $0-$499 for serving as a grant review panel with National Institutes of Health. Dr. Moss has a non-compensated relationship as a Board of Directors with North American Neuro-ophthalmology Society that is relevant to AAN interests or activities.
Kathryn Sands (Verana Health) No disclosure on file
Peng Jin No disclosure on file
Jeremy Peavey No disclosure on file
Craig Pfeifer (Verana Health) No disclosure on file
Youssef Zarrouk (Verana Health) No disclosure on file
Zhongdi Chu (Verana Health) No disclosure on file
Michael Mbagwu No disclosure on file
Aracelis Torres (Verana Health) No disclosure on file